[¹⁷⁷Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?

Lancet Oncol. 2018 Jun;19(6):725-726. doi: 10.1016/S1470-2045(18)30268-7. Epub 2018 May 8.

Authors

Giovanni Paganelli¹, Ugo De Giorgi²

Affiliations

¹ Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRST) IRCCS, 47014 Meldola, Italy. Electronic address: giovanni.paganelli@irst.emr.it.
² Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRST) IRCCS, 47014 Meldola, Italy.

PMID: 29752181
DOI: 10.1016/S1470-2045(18)30268-7

No abstract available

Publication types

Comment

MeSH terms

Dipeptides
Heterocyclic Compounds, 1-Ring
Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant*
Radioisotopes

Substances

Dipeptides
Heterocyclic Compounds, 1-Ring
PSMA-617
Radioisotopes
Prostate-Specific Antigen